colchicine
Trade name: colbenemid
Approved
Jul 27, 1961
Colchicine is an alkaloid obtained from the plant colchicum autumnale (also known as "meadow saffron"). Colchicine is an alternative medication for those unable to tolerate NSAIDs in gout. Mechanism of action of colchicine is inhibition of microtubule polymerization by binding to tubulin. Availability of tubulin is essential to mitosis, so colchicine effectively unctions as a "mitotic poison" or spindle poison. — NCATS
Clinical trial activity
259 trials · 259 clinical orgs · 36 marketing orgs
Earliest trial started Nov 1, 1989 (NCT00004748)
Timeline
1960s
1970s
- Apr 7, 1975
Watson Pharmaceuticals — Marketing Organization
- Mar 11, 1976
Beecham — Marketing Organization
- Jun 12, 1978
Ani Pharmaceuticals — Marketing Organization
- Sep 6, 1979
Lederle — Marketing Organization
- Sep 6, 1979
American Cyanamid — Marketing Organization
1990s
- Jan 1, 1990
Earliest Phase 1 Sponsor(trial)
2000s
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
- May 13, 2008
Novast Labs — Marketing Organization
- May 13, 2008
Ingenus Pharmaceuticals — Marketing Organization
- Jul 29, 2009
Takeda — NDA Secondary Org
- Jul 30, 2009
AR Holding Co Inc — NDA Secondary Org
2010s
- Sep 26, 2014
Hikma — NDA Secondary Org
- Feb 12, 2015
Par Pharmaceuticals — Marketing Organization
- Sep 28, 2016
Amneal Pharmaceuticals — Marketing Organization
- Nov 29, 2018
Endo Pharmaceuticals — Marketing Organization
- Nov 29, 2018
Bristol-Myers Squibb — Marketing Organization
- Nov 29, 2018
PH HEALTH — Marketing Organization
- Jan 30, 2019
Romeg Theraps Llc — NDA Secondary Org
- Jan 30, 2019
Avion Pharmaceuticals — NDA Secondary Org
- Jan 30, 2019
Scilex Pharms Inc — Marketing Organization
- Jan 30, 2019
Sorrento Therapeutics, Inc. — NDA Secondary Org
- Feb 8, 2019
Alkem Labs Ltd — Marketing Organization
- Feb 19, 2019
Zydus Discovery DMCC — Marketing Organization
- Jul 31, 2019
AbbVie — Marketing Organization
- Sep 6, 2019
Dr. Reddy's Laboratories — Marketing Organization
- Sep 16, 2019
Mylan — Marketing Organization
2020s
- Feb 5, 2020
Granules India — Marketing Organization
- Aug 13, 2021
Hetero Labs Ltd — Marketing Organization
- Jan 6, 2022
Aurobindo Pharma — Marketing Organization
- Mar 10, 2022
Strides Pharma Science — Marketing Organization
- Jun 16, 2023
AGEPHA PHARMA FZ — Marketing Organization
- Jun 16, 2023
AGEPHA PHARMA FZ — NDA Secondary Org
- Oct 24, 2023
Rising Pharmaceuticals — Marketing Organization
- Apr 29, 2024
Annora Pharma — Marketing Organization
- Feb 13, 2026
Macleods Pharmaceuticals, Ltd — Marketing Organization
- Feb 17, 2026
Micro Labs Ltd India — Marketing Organization
Indications
Approved for
Studied for
- Acute Coronary Syndrome · Phase 4
- Allografts · Phase 4
- Amyotrophic Lateral Sclerosis · Phase 2
- Anesthesia · Phase 4
- Aortic Valve Disease · Phase 3
- Aortic Valve Stenosis · Phase 3
- Arrhythmias, Cardiac · Phase 3
- Arthritis · Phase 2
- Arthritis, Gouty · Phase 2
- Arthritis, Rheumatoid · Phase 2
- Asthma · Phase 3
- Atherosclerosis · Phase 4
- Atrial Fibrillation · Phase 4
- Atrial Flutter · Phase 3
- Behcet Syndrome · Phase 2
- Blood Platelet Disorders · Phase 3
- Calcium Pyrophosphate · Phase 2
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Pancreatic Ductal · Phase 2
- Carcinoma, Transitional Cell · Phase 1
- Cardiomyopathies · Phase 3
- Cardiovascular Diseases · Phase 3
- Catheter Ablation · Phase 2
- Cerebral Amyloid Angiopathy · Phase 2
- Cerebral Hemorrhage · Phase 3
- Cerebral Infarction · Phase 3
- Chagas Disease · Phase 2
- Cholangiocarcinoma · Phase 2
- Chondrocalcinosis · Phase 4
- Colchicine · Phase 4
- Constriction · Phase 3
- Coronary Artery Bypass · Phase 4
- Coronary Artery Disease · Phase 4
- Coronary Disease · Phase 4
- Coronary Restenosis · Phase 4
- Coronavirus Infections · Phase 3
- COVID-19 · Phase 4
- C-Reactive Protein · Phase 4
- Diabetes Mellitus · Phase 3
- Diabetes Mellitus, Type 1 · Phase 2
- Diabetes Mellitus, Type 2 · Phase 2
- Diabetic Nephropathies · Phase 2
- Diarrhea · Phase 2
- Drug-Eluting Stents · Phase 4
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Drugs, Investigational · Phase 2
- Fibrosis · Phase 4
- General Surgery · Phase 4
- Geriatrics · Phase 4
- Healthy Volunteers · Phase 4
- Heart Diseases · Phase 3
- Heart Failure · Phase 4
- Heart Failure, Diastolic · Phase 4
- Heart Failure, Systolic · Phase 4
- Heart Ventricles · Phase 2/Phase 3
- Hepacivirus · Phase 4
- Hepatitis C, Chronic · Phase 2
- HIV · Phase 2
- HIV Infections · Phase 4
- Hypertension · Phase 2
- Hypertriglyceridemia · Early Phase 1
- Hyperuricemia · Phase 2
- IgA Vasculitis · Phase 3
- Inflammasomes · Phase 4
- Inflammation · Phase 4
- Insulin Resistance · Phase 2
- Intracranial Hemorrhages · Phase 2
- Ischemic Attack, Transient · Phase 3
- Ischemic Stroke · Phase 4
- Kidney Diseases · Phase 2
- Kidney Failure, Chronic · Phase 2
- Leukocytes · Phase 2
- Liver Cirrhosis · Phase 1
- Liver Cirrhosis, Biliary · Phase 3
- Lung Diseases · Phase 4
- Metabolic Diseases · Phase 1/Phase 2
- Multiple Myeloma · Phase 3
- Myocardial Infarction · Phase 4
- Myocardial Ischemia · Phase 2
- Myocardial Reperfusion · Phase 2
- Myocardial Reperfusion Injury · Phase 3
- Myocarditis · Phase 3
- Myocardium · Phase 3
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Non-ST Elevated Myocardial Infarction · Phase 3
- Obesity · Phase 2
- Oral Ulcer · Phase 2
- Osteoarthritis · Phase 4
- Osteoarthritis, Hip · Phase 3
- Osteoarthritis, Knee · Phase 4
- Pacemaker, Artificial · Phase 3
- Percutaneous Coronary Intervention · Phase 4
- Pericardial Effusion · Phase 4
- Pericarditis · Phase 4
- Peripheral Arterial Disease · Phase 3
- Pharmacokinetics · Phase 4
- Pleural Effusion · Phase 3
- Pneumonia, Viral · Phase 2
- Polyarteritis Nodosa · Phase 2
- Postoperative Complications · Phase 2/Phase 3
- Postpericardiotomy Syndrome · Phase 3
- Prostatic Neoplasms · Phase 2
- Purpura · Phase 2
- Radiotherapy · Phase 1
- Recurrence · Phase 4
- Renal Insufficiency · Phase 1
- Renal Insufficiency, Chronic · Phase 4
- Renal Replacement Therapy · Phase 1
- Retinal Diseases · Phase 3
- SARS-CoV-2 · Phase 3
- Severe Acute Respiratory Syndrome · Phase 3
- ST Elevation Myocardial Infarction · Phase 4
- Stroke · Phase 3
- Thoracic Surgery · Phase 3
- Thrombosis · Phase 3
- Transcatheter Aortic Valve Replacement · Phase 3
- Vascular Calcification · Phase 3
- Vasculitis, Leukocytoclastic, Cutaneous · Phase 2
- Venous Thromboembolism · Phase 3
- Ventricular Dysfunction, Left · Phase 1
- Ventricular Remodeling · Phase 4
- Vitreoretinopathy, Proliferative · Phase 3
Mechanism of action
- TubulinINHIBITOR
Tubulin inhibitor
Inhibits microtubule assembly
Binds to beta tubulin
- Tubulin beta-4B chain (TUBB4B) ↗
- Tubulin beta-1 chain (TUBB1) ↗
- Tubulin alpha-3C chain (TUBA3C) ↗
- Tubulin alpha-4A chain (TUBA4A) ↗
- Tubulin beta-3 chain (TUBB3) ↗
- Tubulin alpha-1A chain (TUBA1A) ↗
- Tubulin beta-4A chain (TUBB4A) ↗
- Tubulin beta-8 chain (TUBB8) ↗
- Tubulin beta chain (TUBB) ↗
- Tubulin alpha-1B chain (TUBA1B) ↗
- Tubulin alpha-1C chain (TUBA1C) ↗
- Tubulin alpha-3E chain (TUBA3E) ↗
- Tubulin beta-2A chain (TUBB2A) ↗
- Tubulin beta-2B chain (TUBB2B) ↗
- Tubulin beta-6 chain (TUBB6) ↗
Combination products
colbenemi
with probenecid
Also known as col-probeneci, proben-c
Approval history
- approvedJul 27, 1961
Chemistry & pharmacology
SMILES
COC1=CC2=C(C(OC)=C1OC)C3=CC=C(OC)C(=O)C=C3[C@H](CC2)NC(C)=O- Mol. weight
- 399.437 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaColchicine ↗
- NCATSSML2Y3J35T ↗
- ChEMBLCHEMBL107 ↗
Also known as
- cognivida
- colchicin
- colchicin
- colchicina
- colchicina
- colchicine
- colchicine
- colchicine
- colchicine
- colchicine
- colchicine
- colchicine
- colchicine
- colchicine
- colchicine
- colchicine
- colchicinum
- colchicinum
- colchisol
- colcin
- colcrys
- colcrys
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07232069 | Phase 3 | Apr 1, 2026 | Duke University, Harvard University, Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), University of North Carolina at Chapel Hill |
| NCT07287345 | Phase 4 | Dec 31, 2025 | University of Kentucky |
| NCT07247734 | Phase 2 | Dec 1, 2025 | University of Copenhagen |
| NCT06936709 | Phase 4 | Dec 1, 2025 | Geisinger Clinic |
| NCT07145229 | Phase 2 | Aug 26, 2025 | Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. |
| NCT07143136 | Early Phase 1 (Phase 1) | Aug 10, 2025 | Assiut University |
| NCT06802926 | Phase 4 | Jul 31, 2025 | Jiao Tong University |
| NCT07035405 | Phase 3 | Jul 4, 2025 | Capital Medical University |
| NCT07064109 | N/A | Jul 1, 2025 | Huazhong University of Science and Technology |
| NCT07026994 | Phase 2 | Jun 18, 2025 | Chinese Academy of Medical Sciences, Fudan University, Sichuan University |
| NCT06930885 | Phase 3 | Jun 12, 2025 | Hcor Research Institute, Hospital do Coracao |
| NCT07129538 | N/A | May 10, 2025 | Cairo University |
| NCT06279000 | Phase 3 | Apr 1, 2025 | Cantonal Hospital of St. Gallen |
| NCT06855433 | Phase 2 | Apr 1, 2025 | Harvard University |
| NCT06874192 | Phase 1 | Mar 12, 2025 | Virginia Commonwealth University |
| NCT06847204 | Phase 1/Phase 2 (Phase 2) | Feb 24, 2025 | Post-Graduate Medical Institute, Lahore |
| NCT06813079 | Phase 2 | Feb 17, 2025 | University of Toronto |
| NCT07280572 | Phase 3 | Feb 17, 2025 | European Clinical Research Alliance for Infectious Diseases (ECRAID), Utrecht University |
| NCT06998862 | Phase 3 | Feb 12, 2025 | Hospital General Universitario Gregorio Marañon |
| NCT06768294 | Phase 2 | Jan 31, 2025 | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio |
Organizations
Research & Development (259)
Marketing (43)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| AGEPHA PHARMA FZ | For profit | MKTG | Jun 16, 2023 |
| AGEPHA PHARMA FZ | For profit | NDA2 | Jun 16, 2023 |
| AR Holding Co Inc | For profit | NDA2 | Jul 30, 2009 |
| AbbVie | For profit | MKTG | Jul 31, 2019 |
| Alkem Labs Ltd | For profit | MKTG | Feb 8, 2019 |
| American Cyanamid | For profit | MKTG | Sep 6, 1979 |
| Amneal Pharmaceuticals | For profit | MKTG | Sep 28, 2016 |
| Ani Pharmaceuticals | For profit | MKTG | Jun 12, 1978 |
| Ani Pharmaceuticals | For profit | SYN | Jun 12, 1978 |
| Annora Pharma | For profit | MKTG | Apr 29, 2024 |
| Aurobindo Pharma | For profit | MKTG | Jan 6, 2022 |
| Avion Pharmaceuticals | For profit | NDA2 | Jan 30, 2019 |
| Beecham | For profit | MKTG | Mar 11, 1976 |
| Bristol-Myers Squibb | For profit | MKTG | Nov 29, 2018 |
| Dr. Reddy's Laboratories | For profit | SYN | Sep 6, 2019 |
| Dr. Reddy's Laboratories | For profit | MKTG | Sep 6, 2019 |
| Endo Pharmaceuticals | For profit | MKTG | Nov 29, 2018 |
| Granules India | For profit | MKTG | Feb 5, 2020 |
| Granules India | For profit | SYN | Feb 5, 2020 |
| Hetero Labs Ltd | For profit | MKTG | Aug 13, 2021 |
| Hikma | For profit | NDA2 | Sep 26, 2014 |
| Impax Laboratories | For profit | MKTG | — |
| Ingenus Pharmaceuticals | For profit | MKTG | May 13, 2008 |
| Lederle | For profit | MKTG | Sep 6, 1979 |
| Macleods Pharmaceuticals, Ltd | For profit | MKTG | Feb 13, 2026 |
| Merck | For profit | MKTG | Jul 27, 1961 |
| Merck | For profit | NDA | Jul 27, 1961 |
| Micro Labs Ltd India | For profit | MKTG | Feb 17, 2026 |
| Mylan | For profit | SYN | Sep 16, 2019 |
| Mylan | For profit | MKTG | Sep 16, 2019 |
| Novast Labs | For profit | MKTG | May 13, 2008 |
| PH HEALTH | For profit | MKTG | Nov 29, 2018 |
| Par Pharmaceuticals | For profit | MKTG | Feb 12, 2015 |
| Rising Pharmaceuticals | For profit | MKTG | Oct 24, 2023 |
| Romeg Theraps Llc | For profit | NDA2 | Jan 30, 2019 |
| Sandoz | For profit | MKTG | Mar 18, 1980 |
| Scilex Pharms Inc | For profit | MKTG | Jan 30, 2019 |
| Sorrento Therapeutics, Inc. | For profit | NDA2 | Jan 30, 2019 |
| Strides Pharma Science | For profit | MKTG | Mar 10, 2022 |
| Takeda | For profit | NDA2 | Jul 29, 2009 |
| Watson Pharmaceuticals | For profit | MKTG | Apr 7, 1975 |
| Watson Pharmaceuticals | For profit | SYN | Oct 6, 2015 |
| Zydus Discovery DMCC | For profit | MKTG | Feb 19, 2019 |